Mexichem’s Zephex HFA medical propellant manufacturing facility in Cheshire UK has celebrated its 20th anniversary, the company announced. The Cheshire cGMP facility, which opened in 1995, is audited by both the FDA and MHRA. According to Mexichem, 80% of metered dose inhalers worldwide currently use propellants, and over the past 20 years, Zephex propellants have been used in more than 3.5 billion MDIs.
Mexichem Medical Business Manager Simon Gardner said, “This is an important milestone for Zephex and an endorsement of how we maintain the highest levels of propellant gas quality. We pride ourselves on combining this with a comprehensive range of support services to help customers at every step of the way – from formulation science to propellant engineering, and from analytical technique to regulatory advice.”
